stockportfolio.pro
Stocks / INBX vs MLTX
INBX vs MLTX
Inhibrx Biosciences, Inc. and MoonLake Immunotherapeutics side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Inhibrx Biosciences, Inc. (INBX) | MoonLake Immunotherapeutics (MLTX) | |
|---|---|---|
| Market cap | $1.3B | $1.3B |
| Revenue (latest FY) | $1.30M | $0 |
| Net income (latest FY) | $-140.06M | $-227.32M |
| Revenue growth (5y CAGR) | -0.0% | — |
| Net margin | -10773.5% | — |
| Return on equity | -1752.2% | -74.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open INBX — free Open MLTX — freeFrequently asked questions
Which is bigger, INBX or MLTX?
Inhibrx Biosciences, Inc. is larger by market capitalization — $1.3B versus $1.3B.
Which grows faster, INBX or MLTX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.